Brief: Adagene Presents Clinical Data Demonstrating Strong Safety And Early Signals Of Efficacy In Cold Tumors Including Pancreatic And Ovarian Cancers For Anti-Ctla-4 Monoclonal Antibody, Adg116, At Esmo-Io 2021
06/12/2021 18:54
Adagene Inc 978y.F :
* ADAGENE PRESENTS CLINICAL DATA DEMONSTRATING STRONG SAFETY
AND
EARLY SIGNALS OF EFFICACY IN COLD TUMORS INCLUDING PANCREATIC
AND OVARIAN CANCERS FOR ANTI-CTLA-4 MONOCLONAL ANTIBODY, ADG116,
AT ESMO-IO 2021
Source text for Eikon: ID:nGNX37xm4w
Further company coverage: 978y.F
Recent news on Adagene
See all newsBrief: Adagene To Begin Phase 1 Study Of ADG138 For Advanced Solid Tumors In Q4 2026
Brief: Adagene Announces That Third Arc Bio Has Selected First Lead Candidate Under Amended Strategic Collaboration For Development Of Masked Cd3 T Cell Engagers Utilizing Safebody® Technology
Brief: Adagene Inc Announces Offering Of American Depositary Shares
Brief: Adagene Announces FDA Fast Track Designation For Muzastotug (Adg126)
Brief: Adagene Expands SAFEBody Deal With Exelixis To Develop Third Novel Masked Antibody-Drug Conjugate